Ann Arbor, MI – January 9, 2014 – Wellness & Prevention, Inc., a Johnson & Johnson company, is announcing the launch of the Johnson & Johnson Official 7 Minute Workout App, which features a fitness experience that is fast, simple and effective. The app features the popular 7 Minute Workout designed by Chris Jordan, Director […]
Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety Washington, D.C. (January 8, 2014) – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) asking the agency to require biosimilars to bear nonproprietary names that are similar to, but not […]
New Brunswick (January 8, 2014) – Johnson & Johnson Innovation today announced that it is expanding its global incubator presence through a novel collaboration with the Office of the Chief Scientist in Israel and other industry partners to establish a new biotechnology incubator near Israel’s Weizmann Science Park. This is the latest in a series of […]
RARITAN, NJ, January 7, 2014 — Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a […]